Boc-D-Arg(Mts)-OH CHA
Need Assistance?
  • US & Canada:
    +
  • UK: +

Boc-D-Arg(Mts)-OH CHA

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Category
BOC-Amino Acids
Catalog number
BAT-000963
CAS number
200122-86-7
Molecular Formula
C26H45N5O6S
Molecular Weight
555.74
IUPAC Name
(2R)-5-[[amino-[(2,4,6-trimethylphenyl)sulfonylamino]methylidene]amino]-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid;N-cyclohexylcyclohexanamine
Alternative CAS
68262-72-6
Synonyms
Boc-D-Arg(Mts)-OH cyclohexylammonium salt; N-α-(t-Butoxycarbonyl)-N-ω-(2-mesitylenesulfonyl)-D-arginine cyclohexylammonuim salt
Appearance
White solid
Purity
≥ 99% (HPLC)
Melting Point
~130 °C
Storage
Store at 2-8 °C
InChI
InChI=1S/C20H32N4O6S.C12H23N/c1-12-10-13(2)16(14(3)11-12)31(28,29)24-18(21)22-9-7-8-15(17(25)26)23-19(27)30-20(4,5)6;1-3-7-11(8-4-1)13-12-9-5-2-6-10-12/h10-11,15H,7-9H2,1-6H3,(H,23,27)(H,25,26)(H3,21,22,24);11-13H,1-10H2/t15-;/m1./s1
InChI Key
ULFDXRWBFVJDOX-XFULWGLBSA-N
Canonical SMILES
CC1=CC(=C(C(=C1)C)S(=O)(=O)NC(=NCCCC(C(=O)O)NC(=O)OC(C)(C)C)N)C.C1CCC(CC1)NC2CCCCC2

Boc-D-Arg(Mts)-OH CHA, a protected amino acid derivative, finds widespread utility in various peptide synthesis applications. Here are the key applications of Boc-D-Arg(Mts)-OH CHA, presented with high perplexity and burstiness:

Peptide Synthesis: The versatile Boc-D-Arg(Mts)-OH CHA plays a vital role in chemical peptide synthesis, imparting unprecedented stability to arginine residues. Its incorporation ensures the accurate building of arginine within peptide chains, particularly in intricate sequences, enhancing the yield and purity of synthetic peptides, crucial for both research and therapeutic endeavors.

Protein Engineering: Within the realm of protein engineering, Boc-D-Arg(Mts)-OH CHA empowers the generation of arginine-rich domains within proteins. This capability is invaluable for tailoring protein-protein interaction sites or fortifying the stability of therapeutic proteins. The strategic introduction of modified arginine residues can profoundly impact protein folding, stability, and functionality, ushering in new possibilities for protein design.

Bioconjugation: Leveraging Boc-D-Arg(Mts)-OH CHA in bioconjugation methodologies allows for the precise introduction of arginine residues into biomolecules for diverse applications. These molecular modifications can enhance cellular uptake, optimize pharmacokinetics, or facilitate targeted drug delivery. Furthermore, the incorporation of arginine modifications can foster the creation of innovative biomaterials with tailored interactions, expanding the horizons of biomolecular engineering.

Structural Biology: In the domain of structural biology, Boc-D-Arg(Mts)-OH CHA serves as a powerful tool for investigating the impact of arginine modification on protein structures. By incorporating this derivative into protein crystals, researchers gain valuable insights into how arginine alterations influence protein folding dynamics and structural stability. This application is indispensable for unraveling the intricate relationships between protein structure and function, guiding the development of next-generation therapeutic proteins.

1. Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14
Yuri Cho, et al. PLoS One. 2016 Aug 5;11(8):e0160822. doi: 10.1371/journal.pone.0160822. eCollection 2016.
Aptamers are small synthetic oligonucleotides that bind to target proteins with high specificity and affinity. AS1411 is an aptamer that binds to nucleolin, which is overexpressed in the cytoplasm and occurs on the surface of cancer cells. We investigated the therapeutic potential of aptamers in hepatocellular carcinoma (HCC) by evaluating anti-tumor effects and confirming the affinity and specificity of AS1411- and modified AS1411-aptamers in HCC cells. Cell growth was assessed using the MTS assay, and cell death signaling was explored by immunoblot analysis. Fluorescence-activated cell sorting was performed to evaluate the affinity and specificity of AS1411-aptamers in SNU-761 HCC cells. We investigated the in vivo effects of the AS1411-aptamer using BALB/c nude mice in a subcutaneous xenograft model with SNU-761 cells. Treatment with a modified AS1411-aptamer significantly decreased in vitro (under normoxic [P = 0.035] and hypoxic [P = 0.018] conditions) and in vivo (under normoxic conditions, P = 0.041) HCC cell proliferation compared to control aptamers. AS1411- and control aptamers failed to control HCC cell proliferation. However, AS1411- and the modified AS1411-aptamer did not induce caspase activation. Decrease in cell growth by AS1411 or modified AS1411 was not prevented by caspase or necrosis inhibitors. In a microarray, AS1411 significantly enhanced galectin-14 expression. Suppression of HCC cell proliferation by the modified AS1411-aptamer was attenuated by galectin-14 siRNA transfection. Modified AS1411-aptamer suppressed HCC cell growth in vitro and in vivo by up-regulating galectin-14 expressions. Modified AS1411-aptamers may have therapeutic potential as a novel targeted therapy for HCC.
2. Electro-hyperthermia inhibits glioma tumorigenicity through the induction of E2F1-mediated apoptosis
Jihye Cha, et al. Int J Hyperthermia. 2015;31(7):784-92. doi: 10.3109/02656736.2015.1069411. Epub 2015 Sep 14.
Purpose: Modulated electro-hyperthermia (mEHT), also known as oncothermia, shows remarkable treatment efficacies for various types of tumours, including glioma. The aim of the present study was to investigate the molecular mechanism underlying phenotypic changes in oncothermic cancer cells. Materials and methods: U87-MG and A172 human glioma cells were exposed to mEHT (42 °C/60 min) three times with a 2-day interval and subsequently tested for growth inhibition using MTS, FACS and microscopic analysis. To obtain insights into the molecular changes in response to mEHT, global changes in gene expression were examined using RNA sequencing. For in vivo evaluation of mEHT, we used U87-MG glioma xenografts grown in nude mice. Results: mEHT inhibited glioma cell growth through the strong induction of apoptosis. The transcriptomic analysis of differential gene expression under mEHT showed that the anti-proliferative effects were induced through a subset of molecular alterations, including the up-regulation of E2F1 and CPSF2 and the down-regulation of ADAR and PSAT1. Subsequent Western blotting revealed that mEHT increased the levels of E2F1 and p53 and decreased the level of PARP-1, accelerating apoptotic signalling in glioma cells. mEHT significantly suppressed the growth of human glioma xenografts in nude mice. We also observed that mEHT dramatically reduced the portion of CD133(+) glioma stem cell population and suppressed cancer cell migration and sphere formation. Conclusions: These findings suggest that mEHT suppresses glioma cell proliferation and mobility through the induction of E2F1-mediated apoptosis and might be an effective treatment for eradicating brain tumours.
3. Kahweol induces apoptosis by suppressing BTF3 expression through the ERK signaling pathway in non-small cell lung cancer cells
Young-Joo Jeon, et al. Int J Oncol. 2016 Dec;49(6):2294-2302. doi: 10.3892/ijo.2016.3727. Epub 2016 Oct 12.
Kahweol, a diterpene molecule, has antiproliferative effects on several types of human cancer cells, but whether it has apoptotic effect in non-small cell lung cancer (NSCLC) is not known. To explore this possibility, we incubated cells from two NSCLC cell lines, NCI-H358 and NCI‑H1299, with different concentrations of kahweol and used the MTS assay, DAPI staining, propidium iodide staining, Annexin V staining, immunocytochemical test, and western blot analysis to characterize this molecule and the signaling pathway underlying its effects. The kahweol-treated cells showed significantly decreased cell viability, increased nuclear condensation, and an increased number of Annexin V-positive NSCLC cells. Suppression of basic transcription factor 3 (BTF3) was followed by apoptosis induced by kahweol via the ERK-mediated signaling pathway in a dose- and time-dependent manner. In addition, kahweol modulated the protein expression of BTF3 genes involved in cell-cycle regulation and apoptosis-related proteins, resulting in apoptotic cell death. Our results collectively indicated that kahweol inhibited the proliferation of NSCLC cells through ERK-mediated signaling pathways and the downregulation of BTF3.
Online Inquiry
Verification code
Inquiry Basket